CDK4 and breast cancer: However, the tolerability was significantly better in the chemotherapy-free arm, so this phase III study is the first to demonstrate that CDK4/i—ribociclib in this case—in combination with antibodies is not inferior compared to chemotherapy and may, therefore, be an effective and safe treatment option for triple-positive BC patients [83].